Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod Sequential Therapy with Telitacicept in gMG
NCT06827587Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Feb 2025
- Primary completion
- Feb 2026
- Modality
- Antibody Fragments
01
Overview
Randomised, open-label trial of efgartigimod alfa in myasthenia gravis (MG) (3 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Quantitative Myasthenia Gravis Score at 30 weeks. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06827587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06827587.